EVALUATION OF THE PRESENCE OF 2-LTR HIV-1 UNINTEGRATED DNA AS A SIMPLE MOLECULAR PREDICTOR OF DISEASE PROGRESSION

Citation
M. Zazzi et al., EVALUATION OF THE PRESENCE OF 2-LTR HIV-1 UNINTEGRATED DNA AS A SIMPLE MOLECULAR PREDICTOR OF DISEASE PROGRESSION, Journal of medical virology, 52(1), 1997, pp. 20-25
Citations number
28
Categorie Soggetti
Virology
Journal title
ISSN journal
01466615
Volume
52
Issue
1
Year of publication
1997
Pages
20 - 25
Database
ISI
SICI code
0146-6615(1997)52:1<20:EOTPO2>2.0.ZU;2-E
Abstract
In a preliminary cross-sectional analysis of 109 human immunodeficienc y virus type 1 (HIV-1)-infected subjects the presence of 2-long termin al repeat (LTR) unintegrated circular HIV-1 DNA in peripheral blood mo nonuclear cells (PBMC) was found to be associated with both symptomati c infection (P = 0.0037) and low CD4 counts (P = 0.0004). To investiga te the prognostic significance of the presence of 2-LTR HIV-1 DNA, a s ubset of 23 2-LTR-negative and 25 2-LTR-positive asymptomatic individu als were followed up for 12-24 months. The two groups did not differ i n terms of baseline CD4 counts, zidovudine (ZDV) therapy, and duration of HIV-1 infection. Longitudinal analysis of CD4 values did not indic ate a significantly different CD4 outcome between the two groups. Howe ver, when only ZDV-treated subjects were considered, a significant (P = 0.042) decrease in CD4 counts was found at month 24 with respect to baseline in 2-LTR-positive (n = 12) but not in 2-LTR-negative (n = 11) patients. Moreover, when >40% CD4 loss from baseline and/or developme nt of CDC stage B or C symptoms were considered as indicators of disea se progression, there was a significantly higher number of events in t he whole 2-LTR-positive group than in the whole 2-LTR-negative group ( P = 0.0197 at month 12, P = 0.0299 at month 18, P = 0.0373 at month 24 ). Thus, the presence of 2-LTR HIV-1 DNA in PBMC merits further invest igation as a simple, qualitative, molecular predictor of disease progr ession and decreased response to antiretroviral therapy. (C) 1997 Wile y-Liss, Inc.